Literature DB >> 8542048

Hereditary nondystrophic myotonias and periodic paralyses.

F Lehmann-Horn1, R Rüdel.   

Abstract

The hereditary disorders of muscle excitability are now recognized to be caused by defects in the genes encoding muscle ion channels. This led to a new classification of this disease group. The pathophysiology of these disorders has been elucidated on the molecular level to an extent that exceeds the understanding of the disease mechanisms of most other neuromuscular diseases. The seemingly minor variants of the symptom of myotonia were found to be caused by the remarkable difference that either chloride or sodium channel function is impaired. Even more surprising, the basic defects for hyper- and hypokalemic periodic paralysis, often clinically very difficult to distinguish, turned out to be in the sodium and calcium channels, respectively; these channels are considered to have very different functions in muscle physiology. Three new types of myotonic disease, that is, myotonia, fluctuans, myotonia permanens and proximal myotonic myopathy were discovered. An explanation has been provided as to why myotonia congenita may be transmitted as a dominant or recessive trait.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8542048     DOI: 10.1097/00019052-199510000-00014

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   5.710


  15 in total

1.  Pleiotropic effects of a disrupted K+ channel gene: reduced body weight, impaired motor skill and muscle contraction, but no seizures.

Authors:  C S Ho; R W Grange; R H Joho
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

2.  Structural requirements for voltage-dependent block of muscle sodium channels by phenol derivatives.

Authors:  G Haeseler; A Piepenbrink; J Bufler; R Dengler; J K Aronson; S Piepenbrock; M Leuwer
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

Review 3.  Guidelines on clinical presentation and management of nondystrophic myotonias.

Authors:  Bas C Stunnenberg; Samantha LoRusso; W David Arnold; Richard J Barohn; Stephen C Cannon; Bertrand Fontaine; Robert C Griggs; Michael G Hanna; Emma Matthews; Giovanni Meola; Valeria A Sansone; Jaya R Trivedi; Baziel G M van Engelen; Savine Vicart; Jeffrey M Statland
Journal:  Muscle Nerve       Date:  2020-05-27       Impact factor: 3.217

4.  Voltage-dependent blockade of normal and mutant muscle sodium channels by benzylalcohol.

Authors:  G Haeseler; M Mamarvar; J Bufler; R Dengler; H Hecker; J K Aronson; S Piepenbrock; M Leuwer
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

5.  Voltage-dependent block of normal and mutant muscle sodium channels by 4-Chloro-m-Cresol.

Authors:  G Haeseler; M Leuwer; J Kavan; A Würz; R Dengler; S Piepenbrock
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

6.  Rosiglitazone inhibits Kv4.3 potassium channels by open-channel block and acceleration of closed-state inactivation.

Authors:  I Jeong; B H Choi; S J Hahn
Journal:  Br J Pharmacol       Date:  2011-06       Impact factor: 8.739

Review 7.  Investigation of muscle disease.

Authors:  F L Mastaglia; N G Laing
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-03       Impact factor: 10.154

8.  Defective fast inactivation recovery of Nav 1.4 in congenital myasthenic syndrome.

Authors:  W David Arnold; Daniel H Feldman; Sandra Ramirez; Liuyuan He; Darine Kassar; Adam Quick; Tara L Klassen; Marian Lara; Joanna Nguyen; John T Kissel; Christoph Lossin; Ricardo A Maselli
Journal:  Ann Neurol       Date:  2015-03-27       Impact factor: 10.422

Review 9.  Skeletal muscle channelopathies: new insights into the periodic paralyses and nondystrophic myotonias.

Authors:  Daniel Platt; Robert Griggs
Journal:  Curr Opin Neurol       Date:  2009-10       Impact factor: 5.710

Review 10.  The nondystrophic myotonias.

Authors:  Chad R Heatwole; Richard T Moxley
Journal:  Neurotherapeutics       Date:  2007-04       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.